Part 1 of a 2-Part Sharsheret Webinar Series
Zoom Link Sent Upon Registration
Wednesday, August 5, 2026 8pm ET/5pm PT

If you or someone you love has been diagnosed with breast cancer, you may have heard terms like Prosigna, TrueMRD, Oncotype, MammaPrint, and Precise - but what do these tests actually mean, and how do they help guide treatment decisions?
Join Sharsheret for Part 1 of our two-part webinar series on risk of recurrence, where Dr. Noam Drazin, MD will walk us through the landscape of genomic and recurrence risk testing: what each test measures, how results are used, and what questions to ask your medical team.
Bonus for our Embrace Community: We invite members of our Embrace community, those facing metastatic breast cancer or advanced ovarian cancer, to stay on at the end of the webinar for an intimate breakout session with our expert and Bonnie Beckoff, Director of Sharsheret Support Services.
Questions? Contact Melanie Fisher at [email protected].
With support from:
Cooperative Agreement 24-0061 from the Centers for Disease Control and Prevention
*Disclaimer:

